Multi-Modal Mass Spectrometric Imaging of Uveal Melanoma.

Laura M Cole, Joshua Handley, Emmanuelle Claude, Catherine J Duckett, Hardeep S Mudhar, Karen Sisley, Malcolm R Clench

Abstract read

In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Mass spectrometry in ocular drug research.Mass spectrometry reviews
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura M ColeCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.ORCID 0000-0002-2538-6291

Joshua HandleyCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.

Emmanuelle ClaudeWaters Corporation, Wilmslow SK9 4AX, UK.ORCID 0000-0001-5798-2242

Catherine J DuckettCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.

Hardeep S MudharNSOPS, Department of Histopathology, E-Floor, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.

Karen SisleyDepartment of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield S10 2RX, UK.ORCID 0000-0002-5565-2618

Malcolm R ClenchCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix assisted laser desorption ionisation mass spectrometry imaging (MALDI-MSI), was used to obtain images of lipids and metabolite distribution in formalin fixed and embedded in paraffin (FFPE) whole eye sections containing primary uveal melanomas (UM). Using this technique, it was possible to obtain images of lysophosphatidylcholine (LPC) type lipid distribution that highlighted the tumour regions. Laser ablation inductively coupled plasma mass spectrometry images (LA-ICP-MS) performed on UM sections showed increases in copper within the tumour periphery and intratumoural zinc in tissue from patients with poor prognosis. These preliminary data indicate that multi-modal MSI has the potential to provide insights into the role of trace metals and cancer metastasis.

Indexed as

cancer progressiongenetic biomarkersheterogeneitylaser ablation inductively coupled plasmamatrix assisted laser desorption ionisationuveal melanoma mass spectrometry imaging

Identifiers

PMID34436501

DOI10.3390/metabo11080560

PMCPMC8400170

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.